Dose responses and relationships between anticholinergic activity and mood with tricyclic antidepressants. 1972

B Blackwell, and J O Lipkin, and J H Meyer, and R Kuzma, and W V Boulter

UI MeSH Term Description Entries
D007099 Imipramine The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group. Imidobenzyle,Imizin,4,4'-Methylenebis(3-hydroxy-2-naphthoic acid)-3-(10,11-dihydro-5H-dibenzo(b,f)azepin-5-yl)-N,N-dimethyl-1-propanamine (1:2),Imipramine Hydrochloride,Imipramine Monohydrochloride,Imipramine Pamoate,Janimine,Melipramine,Norchlorimipramine,Pryleugan,Tofranil
D008297 Male Males
D010275 Parasympathetic Nervous System The craniosacral division of the autonomic nervous system. The cell bodies of the parasympathetic preganglionic fibers are in brain stem nuclei and in the sacral spinal cord. They synapse in cranial autonomic ganglia or in terminal ganglia near target organs. The parasympathetic nervous system generally acts to conserve resources and restore homeostasis, often with effects reciprocal to the sympathetic nervous system. Nervous System, Parasympathetic,Nervous Systems, Parasympathetic,Parasympathetic Nervous Systems,System, Parasympathetic Nervous,Systems, Parasympathetic Nervous
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004644 Emotions Those affective states which can be experienced and have arousing and motivational properties. Feelings,Regret,Emotion,Feeling,Regrets
D005260 Female Females

Related Publications

B Blackwell, and J O Lipkin, and J H Meyer, and R Kuzma, and W V Boulter
January 1981, Psychopharmacology,
B Blackwell, and J O Lipkin, and J H Meyer, and R Kuzma, and W V Boulter
June 1978, The American journal of psychiatry,
B Blackwell, and J O Lipkin, and J H Meyer, and R Kuzma, and W V Boulter
January 1978, Communications in psychopharmacology,
B Blackwell, and J O Lipkin, and J H Meyer, and R Kuzma, and W V Boulter
January 1988, Clinical neuropharmacology,
B Blackwell, and J O Lipkin, and J H Meyer, and R Kuzma, and W V Boulter
January 1988, Progress in neuro-psychopharmacology & biological psychiatry,
B Blackwell, and J O Lipkin, and J H Meyer, and R Kuzma, and W V Boulter
April 1978, British journal of pharmacology,
B Blackwell, and J O Lipkin, and J H Meyer, and R Kuzma, and W V Boulter
January 1974, Acta psychiatrica Scandinavica. Supplementum,
B Blackwell, and J O Lipkin, and J H Meyer, and R Kuzma, and W V Boulter
January 1993, Psychopharmacology series,
B Blackwell, and J O Lipkin, and J H Meyer, and R Kuzma, and W V Boulter
November 1980, The British journal of psychiatry : the journal of mental science,
B Blackwell, and J O Lipkin, and J H Meyer, and R Kuzma, and W V Boulter
September 1978, The American journal of psychiatry,
Copied contents to your clipboard!